

hVIVO plc
("hVIVO", the "Company" or the "Group")

CEO & CFO Share Purchase

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that on 15 December 2025, Yamin 'Mo' Khan, Chief Executive Officer and Stephen Pinkerton, Chief Financial Officer, purchased shares in the Company as detailed below.

Director	Number of ordinary shares purchased	Purchase price	Resultant holding	Resultant holding as a % of the issued share capital
Yamin 'Mo' Khan	3,310,405	6.04p	8,322,008	1.21%
Stephen Pinkerton	520,000	5.5p	1,270,596*	0.19%

*343,232 of these shares were purchased/are held by Mrs Dolores Pinkerton, wife of Stephen Pinkerton

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

For further information please contact:

hVIVO plc +44 (0)20 7756 1300
Yamin 'Mo' Khan, Chief Executive Officer
Stephen Pinkerton, Chief Financial Officer

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) +44 (0)20 7220 0500
Geoff Nash, Callum Davidson
Trisyia Jamaludin, Harriet Ward
Nigel Birks - Life Science Specialist Sales
Louise Talbot - Sales

Peel Hunt LLP (Joint Broker) +44 (0)20 7418 8900
James Steel, Dr Christopher Golden

Davy (Joint Broker) +353 (0) 1 679 6363
Anthony Farrell, Niall Gilchrist

ICR Healthcare (Financial PR & IR) hVIVO@icrhealthcare.com
Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson



Notes to Editors

hVIVO plc (Ticker: HVO) is full-service Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.

hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London—the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the **hLAB** brand.

Through its German subsidiary, **CRS**, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, **Venn Life Sciences**, offers Early Drug Development Consulting and Biometry services to the biopharma sector.

The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via **FluCamp**. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1	Details of the person discharging managerial responsibilities/person closely associated					
a.	Name of PDMR	Yamin 'Mo' Khan				
2	Reason for notification					
a.	Position/Status	Chief Executive Officer				
b.	Initial notification/ Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a.	Name	hVIVO plc				
b.	LEI	213800VT5KBM7JLIV118				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.001 each ISIN GB00B9275X97				
b.	Nature of the transaction	Purchase of Ordinary Shares				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>No. of Shares</th> <th>Price</th> </tr> </thead> <tbody> <tr> <td>3,310,405</td> <td>6.04p</td> </tr> </tbody> </table>	No. of Shares	Price	3,310,405	6.04p
No. of Shares	Price					
3,310,405	6.04p					
d.	Aggregated information - Aggregated Volume - Price	See above				
e.	Date of the transaction	15/12/2025				
f.	Place of the transaction	London Stock Exchange, AIM Market (XLON)				

1	Details of the person discharging managerial responsibilities/person closely associated					
a.	Name of PDMR	Stephen Pinkerton				
2	Reason for notification					
a.	Position/Status	Chief Financial Officer				
b.	Initial notification/ Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a.	Name	hVIVO plc				
b.	LEI	213800VT5KBM7JLIV118				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.001 each ISIN GB00B9275X97				
b.	Nature of the transaction	Purchase of Ordinary Shares				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>No. of Shares</th> <th>Price</th> </tr> </thead> <tbody> <tr> <td>520,000</td> <td>5.5p</td> </tr> </tbody> </table>	No. of Shares	Price	520,000	5.5p
No. of Shares	Price					
520,000	5.5p					
d.	Aggregated information - Aggregated Volume	See above				

	- Price	
e.	Date of the transaction	15/12/2025
f.	Place of the transaction	London Stock Exchange, AIM Market (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFFLFLIEISELE